» Articles » PMID: 24732026

Body Positioning and Medical Therapy for Infantile Gastroesophageal Reflux Symptoms

Overview
Publisher Wiley
Date 2014 Apr 16
PMID 24732026
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Proton-pump inhibitors (PPIs) reduce acid gastroesophageal reflux (GER) and esophageal acid exposure in infants; however, they do not reduce total GER or symptoms attributed to GER. Reflux is reduced in the left lateral position (LLP). We hypothesize that the effect of LLP in combination with acid suppression is most effective in reducing GER symptoms in infants.

Methods: In this prospective sham-controlled trial, infants (0-6 months) with symptoms suggestive of gastroesophageal reflux disease were studied using 8-hour pH-impedance, cardiorespiratory and video monitoring, direct nurse observation, and a validated questionnaire. Infants demonstrating a positive GER symptom association were randomized to 1 of 4 groups; PPI + LLP, PPI + head of cot elevation (HE), antacid (AA) + LLP, or AA + HE. HE and AA were considered "sham" therapies. After 2 weeks the 8-hour studies were repeated on-therapy.

Results: Fifty-one patients were included (aged 13.6 [2-26] weeks). PPI + LLP was most effective in reducing GER episodes (69 [13] to 46 [10], P < 0.001) and esophageal acid exposure (median [interquartile range] 8.9% [3.1%-18.1%] to 1.1% [0%-4.4%], P = 0.02). No treatment group showed improvement in crying/irritability, although vomiting was reduced in AA + LLP (from 7 [2] to 2 [0] episodes P = 0.042). LLP compared with HE produced greater reduction in total GER (-21 [4] vs -10 [4], P = 0.056), regardless of acid-suppressive therapy. Acid exposure was reduced on PPI compared with AA (-6.8 [2.1] vs -0.9 [1.4]%, pH < 4, P = 0.043) regardless of positional intervention. A post-hoc analysis using automated analysis software revealed a significant reduction in crying symptoms in the PPI + LLP group (99 [65-103] to 62 [32-96] episodes, P = 0.018).

Conclusions: "Symptomatic gastroesophageal reflux disease" implies disease causation for distressing infant symptoms. In infants with symptoms attributed to GER, LLP produced a significant reduction in total GER, but did not result in a significant improvement in symptoms other than vomiting; however, automated analysis appeared to identify infants with GER-associated crying symptoms who responded to positioning therapy. This is an important new insight for future research.

Citing Articles

Safety and efficacy of proton pump inhibitors in preterm infants with gastroesophageal reflux disease.

King E, Horn D, Gluchowski N, OReilly D, Bruschettini M, Cooper C Cochrane Database Syst Rev. 2025; 3:CD015127.

PMID: 40066936 PMC: 11895421. DOI: 10.1002/14651858.CD015127.pub2.


Proton Pump Inhibitors in Pediatric Gastroesophageal Reflux Disease: A Systematic Review of Randomized Controlled Trials.

Fernandez-Gonzalez S, Moreno-Alvarez A, Solar-Boga A Children (Basel). 2024; 11(3).

PMID: 38539331 PMC: 10969042. DOI: 10.3390/children11030296.


Pharmacological treatment of gastro-oesophageal reflux in children.

Tighe M, Andrews E, Liddicoat I, Afzal N, Hayen A, Beattie R Cochrane Database Syst Rev. 2023; 8:CD008550.

PMID: 37635269 PMC: 10443045. DOI: 10.1002/14651858.CD008550.pub3.


Pilot Study of Inclined Position and Infant Gastroesophageal Reflux Indicators.

Paul I, Shedlock K, Schaefer E, Stoute E, Rosen R JPGN Rep. 2023; 4(2):e312.

PMID: 37200720 PMC: 10187856. DOI: 10.1097/PG9.0000000000000312.


Pediatric Laryngopharyngeal Reflux in the Last Decade: What Is New and Where to Next?.

Sofokleous V, Papadopoulou A, Giotakis E, Delides A, Kyrodimos E, Maragoudakis P J Clin Med. 2023; 12(4).

PMID: 36835970 PMC: 9962831. DOI: 10.3390/jcm12041436.